- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02488655
Treatment of Breast Fibroadenoma With FastScan HIFU
Treatment of Breast Fibroadenoma With FastScan High Intensity Focused Ultrasound (HIFU)
Study Overview
Detailed Description
Echopulse is specially designed, manufactured and CE marked for treating breast fibroadenoma. HIFU is a completely alternative to surgery which utilizes high-energy ultrasound to deliver a large amount of sound energy to a focal point to rapidly induce tissue heating to 85-90°C.This initiates tissue coagulation followed by tissue necrosis ablating the targeted area.
In a previous european feasibility study performed at 4 sites (France and Bulgaria), 51 fibroadenomas in 42 patients were treated. The HIFU treatment was well tolerated and showed efficacy (mean volume reduction of 72.5% +/-16.7 at 12 months follow-up.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Sofia, Bulgaria, 1431
- University Hospital of Endocrinology USBALE
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female patients 18 years or older with one diagnosed breast fibroadenoma.
Diagnosis of fibroadenoma must be based on :
- clinical examination,
- ultrasound image alone for patients under 35 years old. For women older than 35 years, a mammogram will be performed in addition to ultrasound. The BI-RADS (Breast Imaging, Reporting and Data System) score of this mammogram must be less than 3.
- histologic confirmation after core needle biopsy by two independent readers (biopsy must be performed at least two weeks before therapy unless a microbiopsy has been already done less than 3 months before inclusion visit and histopathology slices are available).
The requirements for the distance from the skin and the following regions of the fibroadenoma are:
- ≤ 23 mm from the posterior border of the fibroadenoma
- ≥ 5 mm from the anterior border of the fibroadenoma
- ≥ 11mm from the focal point of the HIFU treatment. These criteria shall be evaluated immediately prior to treatment once breast is immobilized and potentially compressed
- The rib cage should not be in the prefocal ultrasound path or behind the target fibroadenoma (minimum distance behind the focal point= 10 mm). This criterion shall only be reached in treatment conditions, once breast is immobilized and potentially compressed.
- Patient's fibroadenoma is 1 cm or greater at its largest dimension
- Fibroadenoma is palpable
- Patient has signed a written informed consent.
Exclusion Criteria:
- Patient who is pregnant or lactating.
- Patient with a BI-RADS score > 2 at the mammogram, or presence of microcalcifications within the lesion.
- Patient with history of breast cancer or history
- Patient with history of laser or radiation therapy to the target breast
- Patient with breast implants in the target breast
- Patient with a breast cyst
- Patient's fibroadenoma not clearly visible on the ultrasound images (in B mode) at the inclusion visit
- Patient participating in other trials using drugs or devices.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Echopulse
Echopulse HIFU
|
HIFU Under ultrasound guidance
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events
Time Frame: 1 day post treatment
|
1 day post treatment
|
Number of participants with adverse events
Time Frame: 3 days post treatment
|
3 days post treatment
|
Number of participants with adverse events
Time Frame: 7 days post treatment
|
7 days post treatment
|
Change from Baseline Patient pain intensity score (100mm visual analog scale) at 1 day
Time Frame: 1 day post treatment
|
1 day post treatment
|
Change from Baseline Patient pain intensity score (100mm visual analog scale) at 3 days
Time Frame: 3 days post treatment
|
3 days post treatment
|
Change from Baseline Patient pain intensity score (100mm visual analog scale) at 7 days
Time Frame: 7 days post treatment
|
7 days post treatment
|
Patient satisfaction questionnaire
Time Frame: 6 months post treatment
|
6 months post treatment
|
Change from Baseline volume of the fibroadenoma at 6 months
Time Frame: 6 months post treament
|
6 months post treament
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Investigator rated evaluation of the device
Time Frame: Post treatment Day 0
|
Post treatment Day 0
|
Number of participants with absence of palpable lesion
Time Frame: 3 months post treatment
|
3 months post treatment
|
Number of participants with absence of palpable lesion
Time Frame: 6 months post treatment
|
6 months post treatment
|
Patient Cosmetic evaluation as measured by questionnaire
Time Frame: 6 months post treatment
|
6 months post treatment
|
Change from Baseline gland vascularization at 3 months
Time Frame: 3 months post treatment
|
3 months post treatment
|
Change from Baseline gland vascularization at 6 months
Time Frame: 6 months post treatment
|
6 months post treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Roussanka Kovatcheva, Prof., roussanka_kov@yahoo.com
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HIFU/BG/FA/FS/2015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Fibroadenoma
-
Second Affiliated Hospital, School of Medicine,...OmixScience Co., Ltd.RecruitingBreast Cancer | Breast Fibroadenoma | Breast HypoplasiaChina
-
University of ChicagoGuerbetCompletedBreast Cancer | Breast Neoplasms | Breast Diseases | Breast FibroadenomaUnited States
-
Medipol UniversityCompletedBreast Cancer | Breast Neoplasms | Breast Diseases | Breast FibroadenomaTurkey
-
TheraclionActive, not recruitingBreast FibroadenomaBulgaria
-
TheraclionCompleted
-
David R. Brenin, MDTheraclion SAS, Paris, FranceCompletedBreast FibroadenomaUnited States
-
University Women's Hospital TübingenTheraclionCompletedBreast FibroadenomaGermany
-
InSightecTerminatedBreast FibroadenomaUnited States, Japan
-
TheraclionRecruitingBreast FibroadenomaUnited States
-
QT Ultrasound LLCCompletedBreast FibroadenomaUnited States
Clinical Trials on Echopulse
-
TheraclionCompleted
-
TheraclionRecruitingBreast FibroadenomaUnited States
-
TheraclionCompleted
-
TheraclionCompletedBreast FibroadenomaGermany
-
The University of Hong KongCompletedBenign Thyroid NodulesHong Kong
-
TheraclionTerminatedBreast FibroadenomaFrance
-
TheraclionKing's College LondonCompletedBreast FibroadenomaUnited Kingdom
-
The University of Hong KongSuspendedPapillary Thyroid MicrocarcinomaHong Kong
-
TheraclionCompletedVaricose Ulcer | Veins Diseases | Vein, VaricoseAustria